



Unifying the care experience.

Appendix 4C





Oneview Healthcare plc

QUARTERLY ACTIVITIES REPORT

APPENDIX 4C


Quarter Ended 30 September 2023

27 October 2023



James Fitter, CEO, Oneview Healthcare (4th from left) pictured at a meeting with Simon Coveney, Irish Minister for Enterprise, Trade and Employment, Julie Brewer, President Care & Connectivity Solutions, Baxter International Inc and Jordan Sylvester, Vice President, Care Communications & Site Leader, Baxter International Inc, at Baxter's Chicago headquarters on 17th October. Oneview has a strategic collaboration with Baxter whereby Baxter will integrate Oneview's Care Experience Platform (CXP) into their offerings, enhancing patient engagement and streamlining healthcare delivery.

Oneview



**A\$22.8m Capital
Raise
Completed**



**Strong Sales
Pipeline**



**1 New Logo
Added**



**BYOD
Development
On Track**



**> 16,000
Contracted Beds**



**Oneview installed in
Baxter Customer
Experience Center**



ASX Release

Appendix 4C – Q2 2023 Quarterly Cash Flow Report

27 October 2023 – Melbourne, Australia – Oneview Healthcare PLC (ASX:ONE) (“Oneview” or “the Company”), a global healthcare technology company, today released its Appendix 4C – Quarterly Cashflow report for the quarter ending 30 September 2023 (Q3 FY23).

Financial Highlights

The Company had a net operating cash outflow of €3.7m, which follows the typical trend for Q3 in each year. Outgoings trend higher due to annual insurance premiums and audit fees being payable at this time. Customer receipts are at their lowest level, as the volume of customer renewals in this quarter is low compared to other quarters. The bulk of customer receipts occur in the fourth quarter of each year due to the timing of annual customer renewals.

Key components of the operating cash outflow in the quarter comprised:

- Receipts from customers totalled €1.3m. (A\$2.1m). (An additional €1.3m forecast for receipt in Q3 was received in the second week of Q4).
- Deposits of €420k were paid in respect of OEM hardware in the quarter, enabling us to avail of volume discounts and continue to prepare for the imminent sales launch with Baxter. Advance hardware payments for stock purchased to resource contracts in flight were made in the period. This is a timing difference, with customer receipts from sale of same due in Q4 2023.
- Payments in respect of staff costs of €2.4m (A\$3.4m) were 13% higher than the previous quarter as we upscale to resource fulfilment of demand expected from the Baxter VAR and commenced BYOD product development.
- Admin and corporate costs of €832k (A\$1.4m) were in line with the prior quarter. Insurance costs of €450k (A\$0.7m) were paid in the quarter and a financing facility was arranged to pay the sizable D&O premium monthly to smooth cashflows.

The Company held cash balances of €12.2m (A\$20.1m) at 30 September 2023, with zero debt. The Company completed a placement of CHESS depositary interests over fully paid ordinary shares in the Company (CDIs) on 24 July 2023 to institutional and sophisticated investors, which raised A\$20m in gross proceeds. An over-subscribed Security Purchase Plan (SPP) was also completed in August 2023 which raised A\$2.8m in gross proceeds.

Payments to related parties of the entity and their associates in the quarter were comprised of directors' fees totalling €92,000 (A\$152,000).

Operational Highlights

- Oneview Healthcare plc and Children's Health Ireland ("CHI") have signed a seven-year partnership, whereby Oneview will deliver its innovative care experience platform to the new children's hospital, currently under construction. This is significant as it is the first deployment of Oneview's CXP Cloud Enterprise platform in Europe. The initiative will cover over 600 various hospital locations including 363 inpatient and day care units and a further 197 outpatient locations throughout this new state-of-art campus in Dublin. Implementation commenced in September and initial purchase orders have been received.
- University of California San Francisco ("UCSF"), the Company's first US customer, signed a 3-year extension to their existing contract, marking their fourth renewal since the system went live in February 2015.
- Bumrungrad International Hospital, Thailand have signed the contract for an upgrade to Oneview's next-generation platform (Gen 3) in 600 beds, making them the company's first CXP Cloud Enterprise customer in Southeast Asia. The contract is now extended for a further 3 years.
- A further three net new logos are in late-stage contract negotiation, representing 3,200 new beds, demonstrating renewed commercial activity post pandemic.
- Two of the BJC expansion sites are now live. Work is underway at BJC's third expansion hospital and beds will start to go live in Q4 23.
- Catholic Health – the initial Mercy site underway and contract negotiation is underway for an additional 5 locations.
- Operationalization of the Baxter partnership is continuing. Oneview is now installed at Baxter's Customer Experience Centres (CEC) in Batesville, IN and Irvine, CA.
- Oneview participated in a joint Enterprise Ireland and IDA Ireland Trade Mission to Illinois, Indianapolis and Michigan led by Minister for Enterprise, Trade and Employment, Simon Coveney T.D. on 17 October 2023. The purpose of the mission is to boost trade relationships with key IDA client companies and promote world class Irish companies in the Mid-West region of the US. This included a meeting with the Irish Minister and senior executives from Baxter International, held at Baxter's headquarters.
- A scheduled software release was delivered in the quarter, R5, which includes Oneview's production-ready Virtual Care API, enabling Oneview to interoperate with virtual care platforms to bring one-way observation and two-way video consultations to the patient's television. This is an important step in Oneview's Connected Patient Room strategy, enabling new hybrid care models. Caregility is the first partner certified with the Virtual Care API, with other virtual care platforms currently in the certification process.
- Development of the Bring-Your-Own-Device (BYOD) product commenced and is on schedule for the completion of the first development phase at the end of October, enabling pilots to commence. Pilot customers are confirmed in the US and Ireland.
- Oneview hosted a senior delegation from NYU Langone Health in our Dublin offices for two days of design workshops as part of the co-design of the BYOD product. NYU Langone Health is the #1 ranked healthcare system in New York and #3 ranked healthcare system in the United States. A key output from the workshops was the opportunity to collaborate on the "hospital room of the future" in preparation for a new medical centre that NYU Langone are planning, at Nassau Community College in Garden City, N.Y., that will span more than 40 acres and cost \$3 billion. NYU Langone Health have partnered with Oneview since 2017 and recently doubled their deployment to over 2,000 patient locations.

- Mark Cullen and Barbara Nelson have been appointed to the Board of Directors, subject to confirmation of appointment at today's AGM. Mark is rejoining the Board after recently retiring from a distinguished 30-year career with Deutsche Bank and DWS Asset Management. Barbara is a public board director and C-level technology leader, who currently serves on three corporate boards, one which recently launched a successful IPO. Dr Lyle Berkowitz has retired from the Board, also effective 1 October 2023.

Outlook

This is a very exciting time for the Company as we look to continue to capitalise on pent up demand for bedside technology.

Formal launch of the Baxter/Oneview partnership is planned for the second week of November.

Development of the BYOD product is underway and agreements to pilot the product have been confirmed in both the United States and Europe.

Over the past 12 months, our largest US customers, NYU Langone, BJC and UCSF, have all extended and expanded their partnerships with Oneview. UCSF have signed their fourth 3 year extension in this quarter. The fact these discerning customers are expanding and extending their partnerships clearly confirms that we have a product that is scalable and delivering real value.

Sales opportunities are progressing well through the pipeline. We look forward to updating the market as contracts are signed. It should be noted that enterprise contracts in healthcare are complex and when we have been selected as vendor of choice, there is no guarantee that the issuing party will ultimately procure our solution if, for example, hospital budgets remain constrained or their IT priorities change.

ESG

The Company is committed to its Environmental, Social and Governance principles and is pleased to report continued progress, as measured against the World Economic Forum universal ESG framework. Details can be found [HERE](#) on our website and will continue to be reported on a quarterly basis.

This announcement has been approved for release by the board of Oneview Healthcare plc.

About Oneview Healthcare plc

For healthcare systems who lead on exemplary care, Oneview Healthcare plc provides digital tools for patients, families and caregivers to improve the care experience. Unifying a facility's systems, content and services into one digital platform with dedicated devices at the point of care, Oneview helps deliver more control for patients and families, more time for care teams, and less complexity for executives and IT teams. Oneview is proud to partner with leading healthcare systems in the US, Australia, the Middle East and Asia to unify the care experience, in over 70 hospitals.

Enquiries:

James Fitter, CEO

Helena D'Arcy, CFO

Website : www.oneviewhealthcare.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Oneview Healthcare PLC

ABN

610 611 768

Quarter ended ("current quarter")30th September 2023

Consolidated statement of cash flows	Current quarter €'000	Year to date (9 months) €'000
1. Cash flows from operating activities		
1.1 Receipts from customers	1,257	5,417
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(1,623)	(3,373)
(c) advertising and marketing	(128)	(334)
(d) leased assets	-	-
(e) staff costs	(2,400)	(6,825)
(f) administration and corporate costs	(832)	(2,432)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes (paid)/refunded	8	(32)
1.7 Government grants and tax incentives	-	-
1.8 Legal claim recovery, net of costs	-	-
1.9 Other (termination costs)	-	(121)
1.10 Other (working capital movements)	(23)	408
1.11 Net cash from / (used in) operating activities	(3,741)	(7,292)

2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(51)	(222)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(51)	(222)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	13,840	13,840
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(501)	(501)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	13,339	13,339

Quarterly cash flow report for entities subject to Listing Rule 4.7B

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	2,611	6,410
4.2	Net cash from / (used in) operating activities (item 1.11 above)	(3,741)	(7,292)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(51)	(222)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	13,339	13,339
4.5	Effect of movement in exchange rates on cash held	12	(65)
4.6	Cash and cash equivalents at end of period	12,170	12,170

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter €'000	Previous quarter €'000
5.1	Bank balances	12,170	2,611
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	12,170	2,611

6.	Payments to related parties of the entity and their associates	Current quarter €'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	92
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7. Financing facilities	Total facility amount at quarter end €'000	Amount drawn at quarter end €'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. Estimated cash available for future operating activities	€'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(3,741)
8.2 Cash and cash equivalents at quarter end (item 4.6)	12,170
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	12,170
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	3.25
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer:	N/A
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer:	N/A
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer:	N/A
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date:27 October 2023.....

Authorised by: **BY THE BOARD**.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.